ReviewThe mechanism of action of MF59 – An innately attractive adjuvant formulation
Highlights
► MF59 is a safe and well established vaccine adjuvant. ► The mechanism of action of adjuvants is often poorly defined. ► A key component of the mechanism of action of MF59 is cellular recruitment to the injection site. ► MF59 creates a local immunocompetent environment at the injection site.
Section snippets
Introduction – the current status of MF59 adjuvant
MF59 is a well established, safe and potent emulsion-based vaccine adjuvant that has been licensed in more than 20 countries for more than 14 years, for use in an improved influenza vaccine focused mainly on elderly subjects (Fluad®). The overall safety profile of MF59 has been established clinically with a large safety database [1] and through an extensive pharmacovigilance evaluation of the greater than 85 million doses that have been distributed commercially (data from 27 million subjects
The importance of the mechanism of action of vaccine adjuvants
Over the years, we have undertaken extensive evaluations designed to gain insights into the mechanism of action of MF59. We believed that this was important, although as the mechanism of action of adjuvants has been generally understudied for a long time and the importance has been under much appreciated.
In the literature, vaccine adjuvants are frequently classified into two broad groups, called delivery systems, like Alum or MF59, and immune potentiators, like monophosphoryl lipid A (MPL) or
The early origins of the MF59 adjuvant
The MF59 emulsion was originally developed to facilitate the co-delivery of antigen with N-acetyl-l-alanyl-d-isoglutanimyl-l-alanine-2-(1,2-dipalmitoyl) (abbreviated to MTP-PE), which is a synthetic version of muramyl dipeptide (MDP), a naturally occurring bacterial cell wall component known to activate innate immunity. MTP-PE is an immune potentiator and was initially added to the emulsion to improve the potency of the adjuvant. In pre-clinical studies in guinea pigs, the combination adjuvant
The detailed mechanism of action of MF59 – what do we know about how it works?
The first studies undertaken to determine the mechanism of action for MF59 adjuvant were performed in Emeryville, CA in the early 1990s, where the adjuvant was first developed at Chiron Vaccines. These studies focused on the simple questions that could be readily addressed using the techniques available at the time. Subsequently in the mid 1990s, and more recently, we have re visited the mechanism of action and gained important insights. However, it is notable that many of the early
Conclusion – summarizing the overall mechanism of action
Over the years, we have tried to adopt a comprehensive approach to determine the mechanism of action of MF59, combining available knowledge in vaccinology and state-of-the-art techniques. Through the recent application of advanced cellular immunology, gene array studies and cell tracing techniques, we have dissected the mechanism in great detail, using human immune cells in vitro and mouse immunization models in vivo. Our combined studies have consistently asked the following questions: which
Acknowledgments
“We are grateful to Giorgio Corsi for artwork and Kristine Karklins for formatting and submission”.
References (35)
- et al.
MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database
Vaccine
(2009) - et al.
Safety of MF59 adjuvant
Vaccine
(2008) MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Expert Rev Vaccines
(2007)- et al.
MF59 adjuvant: the best insurance against influenza strain diversity
Expert Rev Vaccines
(2011) - et al.
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant
Pediatr Infect Dis J
(2009) - Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt H, et al. Efficacy of an MF59® – adjuvanted...
- et al.
Report of the fourth meeting on ‘Influenza vaccines that induce broad spectrum and long-lasting immune responses’, World Health Organization and Wellcome Trust, London, United Kingdom, 9–10 November 2009
Vaccine
(2011) - et al.
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial
Vaccine
(2011) Vaccinate before the next pandemic?
Nature
(2011)- et al.
Immune mechanisms of protection: can adjuvants rise to the challenge?
BMC Biol
(2010)
Trends in vaccine adjuvants
Expert Rev Vaccines
New adjuvants for human vaccines
Curr Opin Immunol
The path to a successful vaccine adjuvant—‘the long and winding road’
Drug Discov Today
Alum adjuvanticity: unraveling a century old mystery
Eur J Immunol
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
Vaccine
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
Proc Natl Acad Sci USA
The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine
J Infect Dis
Cited by (354)
Lentinan-functionalized graphene oxide hydrogel as a sustained antigen delivery system for vaccines
2023, International Journal of Biological MacromoleculesGonococcal microparticle vaccine in dissolving microneedles induced immunity and enhanced bacterial clearance in infected mice
2023, International Journal of Pharmaceutics